A novel K+ competitive acid blocker, YH4808, sustains inhibition of gastric acid secretion with a faster onset than esomeprazole: randomised clinical study in healthy volunteers.

Sojeong YiH LeeS B JangH M ByunS H YoonJ-Y ChoI-J JangK-S Yu

Published in: Alimentary pharmacology & therapeutics (2017)

This study showed that YH4808 produced a rapid, sustained suppression of gastric secretion with good tolerability. The results at YH4808 ≥200 mg/d provide a rationale for further clinical investigations in populations with acid-related diseases.

Keyphrases

clinical trial
open label
double blind
randomized controlled trial
study protocol
angiotensin ii
drug induced